<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11308270</article-id><article-id pub-id-type="pmc">2363898</article-id><article-id pub-id-type="pii">6691748</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1748</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Glaspy</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jadeja</surname><given-names>J Singh</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Justice</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kessler</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Schwartzberg</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rigas</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kuter</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Harmon</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Prow</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Demetri</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Gordon</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Arseneau</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Saven</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Hynes</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Boccia</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>O'Byrne</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Colowick</surname><given-names>A B</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><aff id="aff1">UCLA School of Medicine, 200 Medical Plaza, Suite 120, Los Angeles, CA 90024 USA</aff><aff id="aff2">Hematology-Oncology Associates of Jacksonville, 5742 Booth Road, Jacksonville, FL 32207, US</aff><aff id="aff3">Pacific Coast Hematology Oncology Medical Group, 11190 Warner Avenue, Suite 300, Fountain Valley, CA 92708, USA</aff><aff id="aff4">Virginia Oncology Associates, 895 Middle Ground Blvd, Newport News, VA 2360, USA</aff><aff id="aff5">Tyler Cancer Center, 910 East Houston, Tyler, TX 75702, USA</aff><aff id="aff6">The West Clinic, 1775 Moriah Woods Boulevard, Suite 5, Memphis, TN 38117, USA</aff><aff id="aff7">Dartmouth Medical School, Norris Cancer Center, Lebanon, NH 03756, USA</aff><aff id="aff8">Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA</aff><aff id="aff9">Texas Cancer Care, Klabzuba Tower, 1300 W. Terrell, Suite 2060, Fort Worth, TX 76104, USA</aff><aff id="aff10">Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA</aff><aff id="aff11">San Antonio Tumor and Blood Clinic, 215 Quincy, Suite 314, San Antonio, TX 78215, USA</aff><aff id="aff12">Albany Regional Cancer Center, 317 South Manning Boulevard, Suite 330, Albany, NY 12208, USA</aff><aff id="aff13">Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA</aff><aff id="aff14">Cancer Center of Kansas, Suite 403, 818 North Emporia, Wichita, KS 67214, USA</aff><aff id="aff15">Associates in Oncology and Hematology, 9707 Medical Center Drive, Shady Grove Medical Building, Rockville, MD, USA</aff><aff id="aff16">Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91329, USA</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>2001</year></pub-date><volume>84</volume><issue>Suppl 1</issue><fpage>17</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &#x000a9; 2001 Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal failure. NESP is biochemically distinct from rHuEPO, due to its increased sialic acid content. NESP has an approximately 3-fold greater half-life. rHuEPO has been shown to be safe and effective for the treatment of chemotherapy-induced anaemia. This study assessed the safety and efficacy of NESP administered once per week, under the supervision of a physician, to patients with solid tumours who were receiving multicycle chemotherapy for up to 12 weeks. Three dose cohorts are presented in this sequential, unblinded and dose-escalating study. Thirteen to 59 patients received NESP (0.5, 1.5 or 2.25&#x02008;mcg&#x02008;kg<sup>&#x02212;1</sup>wk<sup>&#x02212;1</sup>) in each cohort. Patients were monitored for adverse events, including antibody formation to NESP and for effects on haemoglobin. NESP appeared to be well tolerated. Adverse events were similar across all cohorts and were consistent with the population being studied. No antibody formation was detected over the 16-week study period and follow-up. A dose&#x02013;response relationship was evident for NESP and multiple measures of efficacy, including proportion of patients responding to NESP and the mean change in haemoglobin by week 4 and end of treatment for NESP 0.5, 1.5 and 2.25 mcg kg<sup>&#x02212;1</sup>wk<sup>&#x02212;1</sup>cohorts (mean change in haemoglobin at end of treatment was 1.24, 1.73 and 2.15 g dl<sup>&#x02212;1</sup>respectively). Controlled studies of this agent at higher doses and less frequent schedules of administration are ongoing. &#x000a9; 2001 Cance Cancer Research Campaign</p></abstract><kwd-group><kwd>anaemia</kwd><kwd>cancer</kwd><kwd>chemotherapy</kwd><kwd>darbepoetin alfa</kwd><kwd>solid tumours</kwd><kwd>transfusion</kwd></kwd-group></article-meta></front></article>
